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A B S T R A C T   
Pyridoxal 5́-phosphate (PLP) is an important cofactor for amino acid decarboxylases with many biological 
functions, including the synthesis of signalling molecules, such as serotonin, dopamine, histamine, γ-amino-
butyric acid, and taurine. Taurine is an abundant amino acid with multiple physiological functions, including 
osmoregulation, pH regulation, antioxidative protection, and neuromodulation. In mammalian tissues, taurine is 
mainly produced by decarboxylation of cysteine sulphinic acid to hypotaurine, catalysed by the PLP-dependent 
cysteine sulphinic acid decarboxylase (CSAD), followed by oxidation of the product to taurine. We determined 
the crystal structure of mouse CSAD and compared it to other PLP-dependent decarboxylases in order to identify 
determinants of substrate specificity and catalytic activity. Recognition of the substrate involves distinct side 
chains forming the substrate-binding cavity. In addition, the backbone conformation of a buried active-site loop 
appears to be a critical determinant for substrate side chain binding in PLP-dependent decarboxylases. Phe94 was 
predicted to affect substrate specificity, and its mutation to serine altered both the catalytic properties of CSAD 
and its stability. Using small-angle X-ray scattering, we further showed that CSAD presents open/close motions in 
solution. The structure of apo-CSAD indicates that the active site gets more ordered upon internal aldimine 
formation. Taken together, the results highlight details of substrate recognition in PLP-dependent decarboxylases 
and provide starting points for structure-based inhibitor design with the aim of affecting the biosynthesis of 
taurine and other abundant amino acid metabolites.   
1. Introduction 
Pyridoxal 5-phosphate (PLP), the active form of vitamin B6, is a 
ubiquitous cofactor essential for a number of enzymes. PLP-dependent 
enzymes, which mainly use PLP as a covalently bound coenzyme, ac-
count for 4% of total cellular enzymatic activity (Percudani and Per-
acchi, 2003; Thornton et al., 2000). Mammalian genomes encode 
several PLP-dependent enzymes, which catalyse a variety of biochemical 
reactions using different substrates (Percudani and Peracchi, 2003; 
Liang et al., 2019). Many PLP-dependent enzymes use amino acids as 
substrates and play central roles in cellular metabolism. 
PLP-dependent enzymes are established drug targets in cancer and 
neurological diseases. Inhibitors of γ-aminobutyric acid (GABA) 
aminotransferase are of therapeutic interest in central nervous system 
disorders, being used in the treatment of epilepsy (Sarup et al., 2003), 
and inhibitors of L-DOPA decarboxylase (DDC) are used in treating 
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Parkinson’s disease (Bartholini and Pletscher, 1975; Sletzinger et al., 
1963). Furthermore, recessive mutations in PLP-dependent enzymes are 
associated with severe neurological syndromes (Brun et al., 2010; Ercan- 
Sencicek et al., 2010; Haavik et al., 2008). PLP-dependent enzymes can 
be autoantigens and targets of the immune system in autoimmune dis-
orders, e.g. Glu decarboxylase 65 (GAD65; GAD2) in type 1 diabetes 
(Baekkeskov et al., 1990), GAD67 (GAD1) and GAD65 in several 
neurological disorders (Graus et al., 2020), and cysteine sulphinic acid 
decarboxylase (CSAD) in autoimmune polyendocrine syndrome 1 
(Sköldberg et al., 2004). 
The sulphur-containing amino acid taurine is the most abundant free 
amino acid in mammals (Lourenco and Camilo, 2002; Samuelsson et al., 
2012, 2013). Taurine is implicated in numerous physiological functions 
and attracts increasing attention as a biomarker for different disease 
states (Lourenco and Camilo, 2002; Samuelsson et al., 2012, 2013). It 
has a regulatory role in the maintenance of osmotic pressure and 
structural integrity of biological membranes (Hoffmann and Pedersen, 
2006; Schaffer et al., 2010). In the nervous system, taurine may serve as 
a growth factor (Hernandez-Benitez et al., 2010; Pasantes-Morales and 
Hernández-Benítez, 2010) or a neurotransmitter/neuromodulator (Jia 
et al., 2008; Lähdesmäki et al., 1977). In many species, taurine defi-
ciency can be lethal or associated with severe disease (Hoffmann and 
Pedersen, 2006), and in humans, altered levels of taurine have been 
reported in e.g. attention deficit hyperactivity disorder and autism 
(Hobert et al., 2014). In addition, taurine levels significantly decrease 
after electroconvulsive treatment in depressed patients, and this 
decrease strongly correlated with clinical improvements (Samuelsson 
et al., 2012, 2013). Plasma taurine levels were reduced by 83% in CSAD- 
deficient mice, and most offspring from 2nd-generation Csad-/- mice died 
shortly after birth, unless given taurine supplementation (Park et al., 
2014), indicating a crucial physiological role for CSAD in taurine 
biosynthesis. 
In mammalian tissues, taurine is mainly synthesised from cysteine in 
a three-step pathway, involving oxidation by cysteine dioxidase (E.C. 
1.13.11.20), decarboxylation of cysteine sulphinic acid (CSA) by CSAD 
(E.C. 4.1.1.29), and oxidation of hypotaurine to taurine. CSA can addi-
tionally be decarboxylated by the related enzyme glutamic acid 
decarboxylase-like protein 1 (GADL1) (Winge et al., 2015), and taurine 
can be formed from cysteamine by cysteamine dioxygenase (E.C. 
1.13.11.19) (Stipanuk et al., 2009). 
Both CSAD and GADL1 are PLP-dependent decarboxylases (PLP-DC). 
GADL1, being the closest homologue, displays similar activity as CSAD 
(Winge et al., 2015). GADL1 plays a role in the decarboxylation of Asp to 
β-alanine and, thus, functions in the biosynthesis of the abundant di-
peptides anserine and carnosine (Mahootchi et al., 2020). CSAD and 
GADL1 have distinct expression patterns in mouse and human brain 
(Winge et al., 2015). In the brain, CSAD has been detected in neurons 
and astrocytes in the cerebellum and hippocampus (Reymond et al., 
1996; Chan-Palay et al., 1982). GADL1 is expressed in muscle, kidney, 
olfactory bulb, and isolated neurons (Winge et al., 2015; Liu et al., 
2012). CSA is the preferred substrate for both CSAD and GADL1, 
although both are able to decarboxylate cysteic acid (CA) and Asp 
(Winge et al., 2015). 
In an attempt to understand the molecular mechanisms underlying 
the catalysis and regulation of GADL1 and CSAD, and to enable future 
development of optimised inhibitors, we previously solved the crystal 
structure of mouse GADL1 (Raasakka et al., 2018). Here, we determined 
the crystal structure of mouse CSAD (MmCSAD) in the presence and 
absence of PLP. Comparisons of the active sites of PLP-DCs highlight 
substrate recognition determinants within the structurally conserved 
enzyme family. The structure of CSAD helps to understand the details in 
the biosynthesis of taurine, one of the most abundant amino acids and 
dietary supplements. 
2. Results and discussion 
Taurine, the most abundant free intracellular amino acid in humans, 
has been implicated in a range of different physiological functions, and it 
is valuable as an industrial product and dietary supplement. PLP- 
dependent decarboxylation of CSA was observed in liver extracts from 
several mammalian species in the 1950s (Sörbo and Heyman, 1957; 
Chatagner et al., 1958), and since then, the properties of CSAD and 
related PLP-dependent enzymes have been extensively studied. Our aim 
was to better understand biosynthesis of taurine and the substrate 
specificity of PLP-DCs, by way of structural characterisation of CSAD, 
which catalyses the conversion of CSA into hypotaurine (Fig. 1A). 
2.1. The crystal structure of MmCSAD 
A structure of human CSAD has been available at the PDB (entry 
2JIS). However, no detailed information, comparative studies with 
related enzymes, or mechanistic investigations of CSAD are available. 
We solved the crystal structure of MmCSAD, in order to provide a tool for 
further studies on CSAD catalysis and facilitate the design of small 
molecules that could be used to modify taurine-related metabolic 
pathways. 
The crystal structure of MmCSAD was solved at 2.1-Å resolution 
using synchrotron radiation (Table 1, Fig. 1B,C). The active site is fully 
occupied with PLP covalently attached to Lys305 as an internal aldi-
mine, indicating that the structure corresponds to the catalytically 
competent form of MmCSAD. 
The electrostatic potential surface of CSAD (Fig. 1D) shows a high 
positive charge in the active-site cavity, and it is conceivable that this 
property is important in attracting negatively charged substrates. CSAD 
and GADL1 prefer amino acids with short acidic side chains as sub-
strates, i.e. Asp, CA, and CSA, of which CSA is most favoured for both 
enzymes (Winge et al., 2015). On the other hand, Glu, homocysteic acid, 
and homocysteine sulphinic acid have been reported not to be substrates 
of CSAD (Winge et al., 2015; Do and Tappaz, 1996). 
MmCSAD presents the conserved fold of PLP-DCs, with the closest 
structural homologues in the PDB being human CSAD and mouse GADL1 
(Table 2). A sequence alignment of selected homologues with known 
structure is shown in Fig. 2. High structural similarity was expected, 
since the chemical reaction catalysed by PLP-DCs is essentially identical, 
and the substrates differ from each other only by their respective side 
chain moieties. It is possible, however, that substrate side chain recog-
nition in different PLP-DCs may cause small changes in the positioning 
of the reactive groups, thereby leading to different kinetic properties. 
In addition to the catalytically crucial residue Lys305, which in all 
PLP-DCs forms the internal aldimine with PLP, other residues in the 
active site are relevant for substrate binding and catalysis (Fig. 3A). The 
residues interacting with PLP are highly conserved and include His191, 
which is stacked above the PLP aromatic ring. His191 is fully conserved 
in the PLP-DC family, and in addition to fixing PLP in a reactive 
conformation, its roles have been suggested to be central in coordinating 
the carboxyl group that will be released as CO2 (Komori et al., 2012), as 
well as in protonating the quinonoid intermediate resulting from 
decarboxylation (Liang et al., 2019, 2017). 
An additional crystal structure was solved and turned out to be the 
apo form of CSAD, with no electron density for PLP in the active site 
(Supplementary Fig. 1). Hence, this structure represents an inactive 
form of CSAD. The main difference between the apo and holo forms is 
the rotation of the His191 side chain to a conformation not compatible 
with the presence of PLP (Fig. 3B). Overall, the active site of CSAD is less 
ordered in the absence of PLP; thus, PLP binding will stabilise a cata-
lytically competent conformation of the cavity. No larger-scale confor-
mational changes were observed between the apo and holo enzymes, 
which is different from DDC, in which the structure of the apo form 
presented an open conformation, suggested to be linked to the mecha-
nism of cofactor loading (Giardina et al., 2011). Interestingly, both 
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CSAD structures were obtained from the same protein batch, indicating 
that PLP has been lost during crystallisation of the apo form. One pos-
sibility is hydrolysis of the internal aldimine at the slightly acidic pH 
(6.5) of the conditions giving the apo CSAD crystals, eventually leading 
to loss of PLP from the active site. 
2.2. Structure of CSAD in solution 
In addition to the crystal structure, we studied CSAD conformation in 
solution using synchrotron small-angle X-ray scattering (SAXS) (Fig. 4), 
in order to detect possible flexibility, as previously observed for GADL1 
(Raasakka et al., 2018). Indeed, dimeric CSAD behaves much like 
GADL1 in solution, providing evidence for motions between open and 
closed states of the dimer. Such motions might be related to the catalytic 
cycle. They could be linked to the conformation of the flexible catalytic 
loop (residues 330–340), which is not fully visible in the CSAD crystal 
structure. Like in GADL1 (Raasakka et al., 2018), normal mode analysis 
identified an open conformation of the CSAD homodimer, which fits the 
SAXS data well (Fig. 4), but is different from that observed crystallo-
graphically for apo-DDC (Giardina et al., 2011). Whether open/close 
motions are unique to each class of PLP-DCs, or if all family members are 
equally dynamic, remains a subject for future research. 
Fig. 1. Overall structure of MmCSAD. (a) Reactions catalysed by CSAD. CSA is the preferred substrate. (b) Side view of the dimer. The active site is indicated by the 
internal aldimine between PLP and Lys305 (spheres). (c) Top view of the CSAD dimer. (d) Electrostatic surface shows positive potential (blue) in the active-site cavity 
(top view). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 1 
Crystallographic data collection and refinement. Values in parentheses corre-
spond to the highest-resolution shell.  
Structure CSAD holo CSAD apo 
Space group P21 P21 
Unit cell dimensions a = 72.9, b = 113.3, c =
113.4 Å = γ = 90◦, β =
95.8◦
a = 73.1, b = 114.9, c =
113.8 Å = γ = 90◦, β =
95.8◦
Data processing   
Resolution range (Å) 50–2.10 (2.15–2.10) 50–2.80 (2.87–2.80) 
Completeness (%) 90.7 (88.5) 98.6 (98.6) 
Rsym (%) 12.5 (116.5) 42.6 (323.1) 
Rmeas (%) 15.1 (141.1) 50.4 (380.9) 
〈I/σ(I)〉 7.7 (0.9) 3.4 (0.4) 
CC1/2 (%) 99.3 (38.9) 94.9 (18.4) 
Redundancy 2.7 (2.7) 3.4 (3.5) 
Wilson B factor (Å2) 39.2 55.1 
Structure refinement   
Rcryst/Rfree (%) 17.9/23.5 24.3/29.2 
RMSD bond length (Å) 0.007 0.003 








PDB entry 6ZEK 7A0A  
Table 2 
Comparison of the mouse CSAD structure to selected PLP-DCs with known 
structure. Note how decrease in sequence identity has only minor effects on the 









human CSAD 2JIS  0.5 90 – 
mouse GADL1 6ENZ  1.0 62 (Raasakka 
et al., 2018) 
human GAD65 2OKK  0.8 54 (Fenalti et al., 
2007) 
human GAD67 2OKJ  1.0 53 (Fenalti et al., 
2007) 
human HDC 4E1O  2.1 21 (Komori et al., 
2012) 
pig DDC 1JS6  2.2 22 (Burkhard 




6EEI  2.1 13 (Torrens- 
Spence et al., 
2020)  
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2.3. Importance of Phe94 for substrate specificity 
When comparing the structures of CSAD and GAD, it can be 
concluded that Phe94 in CSAD may be important for substrate speci-
ficity. Apparently, Phe94 blocks the binding site for larger substrates; 
hence, Glu should not productively bind (Fig. 5A). The active site of GAD 
has a Ser residue at the corresponding position. In addition, GADL1 has a 
Tyr residue at this position, linked to a slightly different substrate 
preference (Winge et al., 2015). We previously identified this position as 
a key difference in the substrate recognition pocket in the otherwise 
highly homologous acidic amino acid decarboxylases (Mahootchi et al., 
2020). Thus, we mutated Phe94 to Ser in CSAD to evaluate the effects on 
enzymatic properties. 
Activity assays of wild-type (WT) and F94S MmCSAD towards CSA 
and Asp were carried out using HPLC (Table 3, Fig. 5B). While the F94S 
mutation affected both Km and kcat of CSAD towards CSA and Asp, the 
mutant enzyme remained active. Specifically, the effects on Km and kcat 
revealed that F94S has a turnover number 5–10 times lower than WT 
Fig. 2. Sequence alignment of PLP-DCs with known structure. Key elements discussed in the text are highlighted: Phe94 (blue), Ser114/Tyr116 (blue open), α3-α4 
loop (blue dash), His191 (green), Lys305 (red), Tyr335 (green), Arg466 (black). Residue numbering corresponds to MmCSAD. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the web version of this article.) 
Fig. 3. The active site of MmCSAD. (a) Stereo view of the CSAD active site. The bound chloride ion is shown as a green sphere. Elements coming into the active site 
from the opposing monomer are in blue. (b) Comparison of the holo (green/pink) and apo (blue) CSAD active sites. (For interpretation of the references to colour in 
this figure legend, the reader is referred to the web version of this article.) 
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CSAD for both CSA and Asp, indicating an overall effect on catalysis. In 
the mutant, Km increases by an order of magnitude for CSA, but not for 
Asp. Hence, Phe94 is specifically important for the binding of CSA, the 
preferred substrate of CSAD. kcat/Km values further support these ob-
servations, showing that the most effective combination by far is WT 
CSAD with CSA as substrate. 
A test for GAD activity was carried out using Glu as substrate, as the 
mutation F94S mimics the GAD substrate binding site (Fig. 5C). While a 
trace level of activity is observed for WT CSAD, this activity is even 
weaker for F94S. The Km values for both variants are an order of 
magnitude higher than for CSA and Asp. Hence, altering the substrate 
specificity towards Glu requires more than altering the obvious Phe94 to 
the corresponding Ser residue of GAD. Additional factors may include 
protein dynamics, effects of the catalytic loop – not visible in any 
structure of CSAD or GADL1 – as well as minor conformational changes 
in the active site caused by the mutation. 
2.4. Folding and stability of WT MmCSAD and F94S 
The folding and thermal stability of WT MmCSAD and F94S were 
examined using differential scanning fluorimetry (DSF) and circular 
dichroism (CD) spectroscopy. WT MmCSAD and F94S show CD spectra 
with two characteristic minima at 208 and 220 nm. Both spectra are 
essentially identical, indicating correct folding of the mutant (Fig. 5D). 
Both CD spectroscopy and DSF indicate decreased thermal stability for 
the F94S mutant (Table 4). From the CD melting curves, it follows that 
although WT MmCSAD and F94S have similar patterns of melting, F94S 
has a melting temperature ~ 5 ◦C lower than the WT protein (Fig. 5E). 
While the DSF melting curves indicate a similar decrease in stability for 
F94S (Fig. 5F), the mutant appears to open up already at low tempera-
tures. The differences in Tm between the methods, which are commonly 
seen, could be because of differences in the measurement method be-
tween CD and DSF. While CD measures the unfolding of secondary 
structures based on peptide backbone conformation, DSF follows access 
of a small-molecule dye to the protein hydrophobic core. 
The effect of the F94S mutation on the oligomeric state and long- 
term stability of MmCSAD was further studied using size-exclusion 
chromatography (SEC) - multi-angle static light scattering (MALS), 
after freezing and thawing of a pure dimer fraction (Fig. 5G,H). Both WT 
MmCSAD and F94S displayed very similar elution profiles, which mainly 
correspond to a dimer (110 kDa). Both variants also have some tetramer 
and higher-order oligomers after freezing and thawing (Fig. 5H). 
Notably, no monomeric form was detected, indicating high-affinity 
dimerisation; as the active site is formed at the dimer interface, this is 
expected. 
Taken together, the F94S mutation does not affect the secondary 
structure content of CSAD, but it has a clear effect on protein stability. As 
the mutant displays lower activity than the WT enzyme, at least part of 
the effect could be from altered protein dynamics. These data indicate an 
important role for Phe94 in CSAD substrate binding and activity. 
2.5. Comparison of the mouse CSAD active site with other decarboxylases 
As far as enzymatic activity is concerned, CSAD is known to prefer 
CSA as substrate, while having weak activity towards CA and Asp 
(Winge et al., 2015; Do and Tappaz, 1996). The closest homologue, 
GADL1, is more active towards Asp than CSAD, although it is most active 
with CSA as substrate. Based on earlier studies, neither of the enzymes 
accept Glu as substrate, and Glu fails to act as an inhibitor (Winge et al., 
2015), indicating lack of binding to the active site. It is possible that 
close members of the PLP-DC enzyme family have at least partially 
overlapping activities. Based on the observation that mice lacking 
GADL1 have organ-specific reductions of β-alanine and taurine levels, 
we recently suggested that this enzyme might have multiple physio-
logical substrates also in vivo (Mahootchi et al., 2020). On the other 
hand, although our results indicate Glu is a very weak substrate for 
CSAD and GADL1, this activity is unlikely to be of any physiological 
relevance. 
Using the high-resolution crystal structures of both CSAD and 
GADL1, as well as other PLP-DCs (Table 2), one can carry out an in-
spection of the corresponding active-site geometries underlying sub-
strate specificity. As all PLP-DCs catalyse the same chemical reaction, 
amino acid decarboxylation, differences in the active site are expected to 
affect substrate specificity and/or affinity, rather than reaction mecha-
nism per se. Hence, catalytically crucial features are expected to be 
conserved in sequence and 3D structure. For example, His191 is mech-
anistically important in PLP-DCs, possibly being involved in the pro-
tonation of the quinonoid reaction intermediate (Liang et al., 2019). 
Comparison of the apo and holo CSAD structures indicates that the 
conformation of His191 is linked to the presence of the PLP cofactor; it 
can be envisaged that His191 is important for the catalytically compe-
tent orientation of PLP and vice versa. 
A comparison of CSAD and GADL1 should give indications on the 
structural properties causing their differential preference towards Asp, 
Fig. 4. Structure of MmCSAD in solution. (a) SAXS data (grey dots) overlaid with fits from the crystal structure (black), the ab initio model (red), and the normal 
mode-based conformation (blue). (b) Comparison of the crystal structure and models. The open/close motions and the active site location are indicated. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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although CSA is the preferred substrate for both. Asp and CSA have 
slightly different geometries, in that the carboxyl group is planar while 
the sulphinic acid group is not. In addition, for the third known sub-
strate, CA, the molecular size is larger, with 3 oxygen atoms interacting 
with the recognition pocket. In the predicted binding pocket for the 
acidic side-chain group, Phe94 in CSAD is replaced by Tyr in GADL1; 
while the hydroxyl group points away, minor changes in conformation 
and/or dynamics could explain the differences between CSAD and 
Fig. 5. Role of Phe94 in CSAD activity and stability. (a) Superposition of CSAD (grey) and GAD67 (light blue) active sites. The arrow indicates the position of CSAD 
Phe94. The chloride ion in CSAD is shown in green. (b) Activity assay with CSA (filled symbols) and Asp (open symbols). WT, black; mutant, red. (c) Activity assay 
with Glu (filled triangles). WT, black; mutant, red. The activity level of the mutant with Asp is shown for reference (red open circles). (d) CD spectra for WT (black) 
and mutant (red) CSAD. (e) CD melting curves. (f) DSF melting curves. (g) SEC during protein purification; the pure dimer peak at ~ 67 ml was picked for further 
experiments. (h) SEC-MALS after freezing and thawing of dimeric CSAD indicates presence of some higher-order oligomers in both WT and F94S. (For interpretation 
of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 3 
Enzymatic properties of CSAD towards acidic amino acids.   
WT CSAD F94S 



































± 20.9  
0.004  
Table 4 
Thermal stability of WT and F94S MmCSAD.  
Protein DSF Tm (◦C) CD Tm (◦C) 
MmCSAD 56.0 ± 0.2 64.6 ± 0.1 
F94S 51.1 ± 0.2 60.5 ± 0.2  
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GADL1. The Phe94 side chain and backbone of Gln92, Leu93, and Phe94 
are likely to define the binding of the side chain in CSAD substrates 
(Fig. 5A). 
When comparing CSAD and GAD65/67, it becomes obvious that 
Phe94 in CSAD is important for substrate specificity. It blocks the 
binding site for larger substrates, and the Ser residue at this position in 
GAD is likely to form hydrogen bonds to the Glu side chain carboxyl 
group (Fig. 6A). The binding mode of Glu into GAD can be deduced from 
the structure of GAD65 in complex with the inhibitor chelidonic acid 
(Fig. 6A) (Fenalti et al., 2007). Original studies on this line of inhibitors 
indicated that the distance between the two carboxyl groups, corre-
sponding to an extended Glu molecule, is important (Porter and Martin, 
1985). The carboxyl groups of the inhibitor mimic those of Glu, and 
hydrogen bonds are seen to Ser183/192 and a water molecule coordi-
nated by His395/404 at the bottom of the cavity (numbering for 
GAD65/67), and well as to the backbone amide groups of the α3-α4 
recognition loop containing Ser183/192 (see below). The His residue 
and the water molecule are also present in CSAD, and CSA is likely to 
Fig. 6. Comparison to other decarboxylases. (a) GAD65 in complex with chelidonic acid, with hydrogen bonds shown in green. Based on the structure, a proposed 
mode of Glu substrate binding in GAD is shown (cyan). (b) Superposition of the α3-α4 loop in CSAD (grey), GADL1 (green), GAD65 (blue), HDC (magenta), and DDC 
(pink) highlights two subfamilies linked to substrate side chain size and properties. (c) Top: Backbone conformation in acidic amino acid decarboxylases (with 
chelidonic acid). Amino groups from the α3-α4 loop form direct hydrogen bonds (dashes) with the acidic substrate. Bottom: Backbone conformation in HDC and DDC; 
carbonyl groups interact with the substrate via hydrogen bonds and/or van der Waals interactions (dashes). (d) Stereo view of superposed CSAD (gray) and HDC 
(magenta) from two orientations. Key interactions of the α3-α4 loop of CSAD (yellow dashes) and HDC (red dashes) are shown. Additionally, large substituting 
changes between HDC and CSAD, such as Trp72/Thr84, are shown. (e) The α3-α4 loop and the internal aldimine in CSAD (grey) and DDC (orange). The surface at the 
top corresponds to CSAD and the one at the bottom to DDC. The black asterisk marks a volume present in DDC but not in CSAD, arising from the conformation of the 
α3-α4 loop. Relevant residues in the α3-α4 loop are labelled. (For interpretation of the references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
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similarly hydrogen bond to this water molecule. 
HDC has been crystallised with the non-cleavable His methyl ester 
trapped as a PLP adduct, thereby giving insights into the reaction 
mechanisms in the family (Komori et al., 2012). A similar conformation 
was observed for the inhibitor carbidopa in DDC (Burkhard et al., 2001). 
Phe94 in CSAD prevents the binding of such large substrates into the 
active site, but it is, in fact, not the only determinant. Comparing the 
acidic amino acid decarboxylases GAD65, GAD67, CSAD, and GADL1 
with those acting on larger, non-acidic substrates, one should note the 
α3-α4 loop, forming the active site cavity wall and intimately interacting 
with the substrate (Fig. 6B). The backbone conformation of the α3-α4 
loop is different between the two groups of enzymes, and the peptide 
bonds have opposite orientations, such that the NH groups point to-
wards the substrate-binding cavity in GAD, CSAD, and GADL1 (Fig. 6C). 
In HDC and DDC, the carbonyl groups point into the same pocket, giving 
a different electrostatic environment and allowing the binding of posi-
tively charged and neutral substrates, such as His or L-DOPA, into the 
active site (Fig. 6C). 
In addition to the active-site conformation, based on the sequence 
conservation of the α3-α4 recognition loop in PLP-DCs (Fig. 2), CSAD, 
GADL1, and the GADs can be grouped together, while DDC and HDC 
form another group (Fig. 6B). A closer comparison of mouse CSAD and 
human HDC reveals that the loop is formed out of two overlapping 
motifs forming central interactions close to the active site (Fig. 6D). In 
CSAD, the first motif stretches from Phe90 to Phe94, with the consensus 
sequence FNQ[FYS] in the first group. In HDC, the stretch that super-
imposes with this sequence involves Ala79-Pro82, with the consensus 
sequence AY[YF]P in the second group. The backbone trace of this 
segment in both groups is similar, although the underlying interactions 
and side chain conformations differ drastically between CSAD and HDC. 
In group 1, the central Asn residue acts as a hub of weak interactions and 
hydrogen bonds, locking different structural elements in place. For 
CSAD, a noteworthy Asn91-interacting residue is Lys442, which is fully 
conserved in the first group and likely to draw the α3-α4 loop towards 
helix α15. Worth noting is that Arg466 in CSAD (Arg447 in HDC) is fully 
conserved in PLP-DCs discussed above (Fig. 2), but may adopt different 
conformations. Its conservation is linked to its direct mechanistic 
interaction with the substrate ⍺-carboxyl group. 
Strikingly, the second stretch that follows after the conserved motif 
adopts a completely different conformation between the two groups of 
PLP-DCs (Fig. 6D). The conformation is influenced by the Pro residue 
replacing CSAD Phe94 in HDC and DDC, which leads to substantially 
more space in the active site of PLP-DCs with larger, non-acidic sub-
strates (Fig. 6C,E). This is a key substrate binding determinant between 
the two groups of PLP-DCs. In addition to the conformational change 
resulting from the interaction network of the short sequence motifs, the 
rigidity of the α3-α4 loop is most likely different between the two 
groups. HDC and DDC have a conserved Trp residue (Trp72 in HDC), 
which is replaced by Thr84 in CSAD (Fig. 6D); hence, the α3-α4 loop in 
HDC and DDC may be more rigid. This is supported by lower B factors 
for the corresponding region (10 – 11 Å2 in HDC bound to His methyl 
ester (resolution 1.8 Å), 21 – 25 Å2 in apo-DDC (2.6 Å), 27 – 31 Å2 in apo- 
CSAD (2.1 Å)). 
2.6. Substrate specificity and catalytic mechanism of CSAD and GADL1 
The substrate specificity of CSAD has been subject to some contro-
versy. Before the availability of recombinant, purified enzyme, a 
concern was that the ability of CSAD to accept multiple substrates could 
be due to contamination with other enzymes, mainly GAD (Do and 
Tappaz, 1996; Guion-Rain and Chatagner, 1972; Oertel et al., 1981). 
However, we now know that CSA is the preferred substrate for CSAD 
both in vitro and in vivo (Park et al., 2014; Winge et al., 2015; Agnello 
et al., 2013). In addition, CSAD isolated from marine bacteria, insects, 
and several mammalian species accept CA, the oxidised form of CSA, as 
substrate, with 3–13% rate constants relative to CSA (Agnello et al., 
2013; Liu et al., 2012). However, as the concentration of CA in the rat 
brain is 50–80% of CSA, decarboxylation of CA should have minor 
contribution to the overall synthesis of taurine (Ida and Kuriyama, 
1983), at least in brain tissue. In addition, low Asp and Glu decarbox-
ylase activity has been reported for CSAD (Winge et al., 2015; Weinstein 
and Griffith, 1987). Due to the presence of related enzymes with higher 
efficacy towards Asp and Glu (GADL1, GAD65, and GAD67), the phys-
iological importance of such weak activity is unclear. However, the 
ability of the PLP-DCs to process a range of overlapping substrates may 
be metabolically advantageous, as observed for GADL1 knockout mice. 
These mice showed tissue-specific loss of both β-alanine and taurine 
derivatives, depending on the relative tissue abundance of the different 
enzymes (Mahootchi et al., 2020). 
Insect aspartate decarboxylase (ADC), which has high homology and 
similar catalytic properties to CSAD, prefers CSA as substrate, but is also 
active towards Asp and CA (Liu et al., 2012). When ADC was incubated 
with CSA in the presence of each of the 20 proteinogenic amino acids, 
the preferred substrate was still CSA (Liu et al., 2013). Since insect ADC 
and human CSAD share ~ 50% sequence identity (Liu et al., 2019), one 
can expect similar properties for ADC and CSAD. 
A number of ions were detected in the MmCSAD structure; including 
an ion modelled as chloride in each active site (Fig. 3A,5A), interacting 
with the backbone amide groups of loop α3-α4 discussed above. This site 
could be relevant for recognizing the substrate acidic side chain. In the 
structure of HDC with methylhistidine (Komori et al., 2012) covalently 
linked to the PLP cofactor, the binding determinants for the carboxyl 
and amino groups are well defined, while the inhibitor chelidonic acid 
bound to GAD (Fenalti et al., 2007a, 2007b) provides additional infor-
mation. Using these structures as templates, one can dock in CSA, taking 
into account the anion-binding site in the active cavity (Fig. 7). We 
consider the latter to be a likely location for the CSA sulphinic acid 
group binding - or in the case of Asp, the side-chain carboxyl group. 
While both CSA and Asp require two hydrogen bonding partners for the 
side chain, CA needs three – it is likely that two of the hydrogen bonds 
are provided by the backbone amide groups in the α3-α4 loop and the 
third one by the conserved water molecule. 
The leaving carboxyl group, in a perpendicular position to the plane 
formed by the PLP ring and the Schiff base moiety, is stabilised by 
Arg466 (Fig. 7A). It may also be hydrogen-bonded to His191, a central 
residue in the PLP-DC mechanism, as seen in the structure of HDC 
(Komori et al., 2012). In apo CSAD, His191 is rotated, and it will reach 
its correct conformation upon PLP complex formation. Thus, the core 
active site of CSAD appears pre-organised for catalysis, but only in the 
presence of the cofactor internal aldimine. 
A main obstacle in fully understanding the mechanistic details of 
CSAD and GADL1 catalysis is the flexible α12-α13 loop covering the 
active site; this loop is not visible in any of the available CSAD or GADL1 
crystal structures, but a conserved Tyr residue in it has been suggested to 
be a key player in catalysis by PLP-DCs, including GAD (Fenalti et al., 
2007). This Tyr, Tyr335 in CSAD, is conserved in CSAD and GADL1 
(Fig. 2). Importantly, in both DDC and HDC, the loop is susceptible to 
proteolysis, but gets protected, when an active-site ligand is bound 
(Burkhard et al., 2001; Fleming et al., 2004; Ishii et al., 1998). Hence, 
the dynamics of the loop are linked to the decarboxylase reaction cycle 
and occupancy of the active site. After decarboxylation, protonation of 
the reaction intermediate is carried out by Tyr335, which enables the 
reaction to proceed towards product release and reconstitution of the 
internal aldimine in the CSAD active site. The protonation could either 
occur directly (Fenalti et al., 2007) or be mediated through a water 
molecule coordinated by Tyr335 (Fernandes et al., 2017). Intriguingly, 
PLP-DCs can catalyse a different reaction involving molecular oxygen, if 
this Tyr residue is mutated to a Phe (Bertoldi et al., 2002; Bisello et al., 
2020). His191 also appears to be relevant for the protonation step (Liang 
et al., 2019, 2017; Fernandes et al., 2017), but in light of current data, its 
likely role is the coordination of Tyr335. 
A tripartite substrate selectivity motif was identified in GAD and 
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CSAD, in a study focusing on taurine synthesis by marine bacteria 
(Agnello et al., 2013). The residues of this motif are Phe94, Ser114, and 
Tyr116 in CSAD. Essentially, while Phe94 was important for catalysis on 
CSA and CA, replacing Tyr116 with Phe (as in GAD, DDC, or HDC), 
allowed CSAD to use Glu as substrate (Agnello et al., 2013). This brings 
an added level of complexity to the mechanism. Comparing the structure 
of CSAD with the enzymes carrying Phe at this position reveals a 
completely different conformation in the crystal state (Fig. 7B). In HDC 
and GAD, it is clear that the catalytic loop pushes the Phe residue to the 
active site wall, when the Tyr in this loop reaches in for protonation of 
the reaction intermediate. In the structures of CSAD and GADL1, the 
catalytic loop is disordered, and Tyr116 is in a relaxed conformation. 
During the reaction cycle, it must be pushed further in, reducing the 
available space in the active site, but also providing a putative additional 
hydrogen bonding contact for substrate recognition (Fig. 7B). The latter 
could be important in making CSA the preferred substrate for CSAD. 
2.7. Insights into inhibitor design 
Rare mutations in enzymes responsible for the degradation of 
β-alanine, as well as its histidine derivatives carnosine and anserine, 
have been linked to the abnormal accumulation of these compounds in 
mammalian tissues and severe neurological diseases (Scriver et al., 
1966; Willi et al., 1997). As the neurological symptoms have been un-
responsive to dietary interventions, an alternative treatment strategy 
could be to inhibit their biosynthesis. The discovery (Mahootchi et al., 
2020) that GADL1 functions in the biosynthesis of β-alanine and car-
nosine raises the possibility that it could be a target for inhibition 
therapy. The first generation of inhibitors targeting CSAD and GADL1 
had modest affinity but promising selectivity (Winge et al., 2015). Since 
then, high-resolution structures for both enzymes have become avail-
able, providing a stepping stone for further knowledge-based optimi-
sation of such compounds. The differences in activity towards closely 
related substrates, as well as the subtle differences in the respective 
active-site structures, can be utilised in the development of a next gen-
eration of potential inhibitors of acidic amino acid decarboxylases. 
These aspects are crucial in the development of in silico screening 
approaches. 
A prime example of inhibitor design towards PLP-DCs is carbidopa 
(Sletzinger et al., 1963), which is a DDC substrate analogue able to form 
a stable covalent adduct with the PLP cofactor. Carbidopa is in wide use 
in the treatment of Parkinson’s disease, whereby it inhibits the con-
version of L-DOPA to dopamine in peripheral tissues (Bartholini and 
Pletscher, 1975), leading to increased L-DOPA half-life and reduced side 
effects of dopamine. The crystal structure of DDC in complex with car-
bidopa (Burkhard et al., 2001) is, therefore, of high value in designing 
inhibitors towards other PLP-DCs. For example, for acidic amino acid 
decarboxylases, a similar approach targeting the external aldimine 
instead of a simple substrate analogue – as done previously (Winge et al., 
2015; Porter and Martin, 1985; Liu et al., 2013) – would be a promising 
approach. In addition, mechanism-based inhibitors of CSAD activity, 
based on chemical substitutions on the β carbon, have been studied 
(Weinstein and Griffith, 1987; Griffith, 1983). Non-cleavable analogues 
of different stages of the acidic amino acid decarboxylase reaction 
mechanism could, hence, be targeted in a systematic manner instead of 
non-targeted screening or attempts at designing substrate analogues, 
which inherently will have rather low affinity in these enzymes. 
3. Concluding remarks 
Our work highlights central details of molecular mechanisms of 
taurine biosynthesis; in addition, substrate recognition determinants 
across the PLP-DC family have been elucidated. Substrate specificity in 
the family is clearly affected by both the amino acid side chains lining 
the catalytic cavity as well as direct backbone-substrate interactions. 
The latter divide PLP-DCs into two subclasses. These findings are central 
in understanding mechanistic details of catalysis, but also in research 
aimed at designing effectors of amino acid decarboxylation linked to the 
production of important metabolites and signalling molecules, such as 
taurine, β-alanine, carnosine, GABA, histamine, serotonin, and 
dopamine. 
4. Materials and methods 
4.1. Expression vector 
Multiple mRNA transcripts of CSAD have been described, with 
alternative initiation codons and splicing events (Lourenco and Camilo, 
Fig. 7. Implications for the CSAD reaction 
mechanism. (a) Proposed model for CSA 
substrate binding to CSAD and depiction of 
catalytically important residues. Hydrogen 
bonds to active-site side chains, main-chain 
groups, the cofactor, and a conserved water 
molecule are shown in yellow dashes. A van 
der Waals interaction possibly relevant for 
CSAD substrate specificity to Phe94 is in 
green. The blue dash indicates the bond that 
will be formed upon external aldimine for-
mation between Lys305 and CSA. Proton-
ation of the quinonoid intermediate at the 
second stage of the reaction is likely cata-
lysed by Tyr335 from the flexible α12-α13 
catalytic loop (here pictured in the position 
observed in the GAD65 crystal structure), 
from the other subunit. (b) The previously 
identified CSAD/GAD substrate selectivity 
motif consisting of Phe94, Ser114, and 
Tyr116 (Agnello et al., 2013), compared to 
that in HDC (magenta). Note how the 
incoming loop containing the catalytic Tyr 
residue pushes the aromatic residue (Tyr116 
in CSAD) in close contact with the catalytic 
cavity. (For interpretation of the references 
to colour in this figure legend, the reader is 
referred to the web version of this article.)   
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2002). MmCSAD cDNA corresponding to the 493-amino-acid (55 kDa; 
UniProt entry Q9DBE0) isoform was subcloned into the expression 
vector pTH27 (Hammarström et al., 2006), which codes for an N-ter-
minal His6 tag. In order to examine structural determinants of substrate 
specificity of MmCSAD, the variant F94S was generated using the 
QuikChange kit (Agilent). The sequences of expression clones were 
verified by DNA sequencing. 
4.2. Expression and purification of MmCSAD 
WT and F94S His6-CSAD were expressed in Escherichia coli BL21 
CodonPlus (DE3)-RIPL cells (Stratagene) at +15 ◦C using 0.5 mM IPTG 
induction. Pyridoxine hydrochloride, a precursor of PLP biosynthesis, 
was added to the culture at 2 mM to improve protein solubility. Cell 
pellets were lysed by sonication in a buffer consisting of 50 mM sodium 
phosphate buffer pH 7.4, 500 mM NaCl, 20 mM imidazole, 0.2 mg/ml 
lysozyme, 1 mM MgCl2, and cOmplete EDTA-free protease inhibitors 
(Roche). Phenylmethylsulphonyl fluoride was added to 1 mM immedi-
ately following sonication, and the unclarified lysate was applied onto 
an IMAC HiTrap TALON crude column (GE Healthcare). The column was 
washed first with 50 mM sodium phosphate pH 7.4, 500 mM NaCl, and 
then with the same buffer containing 20 mM imidazole. Elution was 
done with 100 mM imidazole in the same buffer. SEC was performed 
using a Superdex HR 200 column (GE Healthcare) equilibrated with 20 
mM HEPES, 200 mM NaCl (pH 7.4). After elution, CSAD dimer fractions 
were combined and concentrated. 
4.3. Crystallisation, data collection, structure solution, and refinement 
MmCSAD crystals were obtained at +20 ◦C using sitting-drop vapour 
diffusion. Holo-CSAD crystals were grown in drops containing 200 nl of 
protein stock (10.3 mg/ml) and 100 nl of reservoir solution (0.15 M KBr, 
30% PEG2000 monomethyl ether), and apo-CSAD crystals grew in drops 
of 100 nl protein and 200 nl reservoir (200 mM Na2SO4, 100 mM Bis-tris 
propane, pH 6.5, 20% PEG3350). Crystals were briefly soaked in a 
cryoprotectant solution containing 80% reservoir solution and 20% 
glycerol, and flash-cooled in liquid N2 prior to data collection. 
X-ray diffraction data were collected at 100 K on the automated 
MASSIF-1 synchrotron beamline at ESRF (Grenoble, France) (Bowler 
et al., 2015; Bowler et al., 2016; Svensson et al., 2015). The data were 
processed and scaled using XDS (Kabsch, 2010). The structure was 
solved by molecular replacement in PHASER (McCoy et al., 2007), using 
the human CSAD crystal structure (PDB entry 2JIS) as template. 
Refinement was done in phenix.refine (Afonine et al., 2012) and model 
rebuilding with Coot (Casañal et al., 2020). The structures were vali-
dated using MolProbity (Chen et al., 2010). 
4.4. Small-angle X-ray scattering 
SAXS data for MmCSAD were collected on the SWING beamline at 
the SOLEIL synchrotron (Gif-sur-Yvette, France). Scattering was 
measured in batch mode at three different protein concentrations (1–2.5 
mg/ml), from a freshly purified monodisperse dimeric sample. The 
recorded frames were checked for radiation damage, and data from all 
concentrations were analysed to exclude interparticle effects. Data were 
processed using the beamline software Foxtrot 3.5.2 and analysed with 
ATSAS (Franke et al., 2017). Ab initio chain-like models were built with 
GASBOR (Svergun et al., 2001), normal mode-based conformations were 
analysed using SREFLEX (Panjkovich and Svergun, 2016), and the 
crystal structure was compared to the SAXS data with CRYSOL (Svergun 
et al., 1995). 
4.5. Sequence and structure analysis 
Structure superpositions were done with SSM (Krissinel and Henrick, 
2004). Sequences were aligned with ClustalW (Thompson et al., 1994) 
and visualised with ESPript (Gouet et al., 1999). Electrostatic surfaces 
were calculated using APBS and pdb2pqr (Unni et al., 2011) and 
visualised in UCSF Chimera (Pettersen et al., 2004). PyMOL 
(Schrödinger) was used for structure visualisation and analysis. 
4.6. Circular dichroism spectroscopy 
CD spectra between 200 and 260 nm were recorded in triplicate on a 
Jasco J-810 instrument. Measurements were done at a protein concen-
tration of 0.6 mg/ml in a 1-mm quartz cuvette. The samples were diluted 
with 10 mM sodium phosphate (pH 7.4), and buffer spectra were sub-
tracted. Thermal denaturation was measured using the CD signal at 222 
nm from +25 to +95 ◦C, at a heating rate of 2 ◦C/min. 
4.7. Differential scanning fluorimetry 
A fluorescence-based thermal stability assay (differential scanning 
fluorimetry, DSF) (Ericsson et al., 2006) was performed using a Light-
Cycler 480 II instrument (Roche). 20-μl samples were analysed in 20 mM 
HEPES, 200 mM NaCl (pH 7.4). CSAD concentration was 0.1 mg/ml, and 
SYPRO® Orange was used at a 1:1000 (v/v) dilution. The instrument 
was set to detect emission between 300 and 570 nm. The heating rate 
was 2 ◦C/min from +20 to +99 ◦C. Five replicates of each sample were 
measured, using a 384-well plate with an optical film (Roche). 
4.8. Quaternary structure analysis 
Analytical SEC-MALS was employed to determine the oligomeric 
states of WT MmCSAD and F94S. SEC was done using the 
ÄKTA™Purifier FPLC system (GE Healthcare), which was coupled with 
a RefractoMax 520 module (ERC GmbH, Riemerling, Germany) for 
measuring refractive index for concentration determination, and a mini- 
DAWN TREOS light scattering detector (Wyatt Technology). Samples 
were diluted to 2 mg/ml and centrifuged at 16 000 g for 10 min at +4 ◦C. 
200 µg of the protein were applied onto a Superdex 200 Increase 10/300 
GL column, pre-equilibrated with 20 mM HEPES, 200 mM NaCl (pH 
7.4), at a flow rate of 0.4 ml/min. Astra software (Wyatt) was used for 
SEC-MALS data analysis. 
4.9. Enzymatic activity assays 
Catalytic activity of WT MmCSAD and F94S towards the known 
substrates CSA and Asp was measured at +37 ◦C, using a reaction 
mixture of 100 μl containing 6 µM CSAD, 60 mM potassium phosphate 
(pH 7.4), 5 mM DTT, and 0.5 μM PLP. Adding the amino acid substrate 
started the reaction. To measure steady-state kinetic properties of the 
enzymes, 0–50 mM of the substrates were tested. After 60 min, the re-
action was stopped by addition of an equal volume of ice-cold ethanol 
containing 5% acetic acid. For studying GAD activity with Glu as sub-
strate, the reaction mixture of 100 μl contained 60 mM potassium 
phosphate (pH 7.4), 5 mM DTT, and 2 mM PLP, and the reaction was 
stopped after 120 min. 
The samples were centrifuged at 15,700 g for 10 min, and the su-
pernatant was transferred onto a microtiter plate and analysed by HPLC. 
Samples were diluted with an equal volume of solvent (24% ethanol in 
50 mM sodium phosphate, pH 6.0), and 4.2% o-phtaldialdehyde (OPA) 
reagent was added. Mobile phase was a mix of 50% of 100 mM sodium 
phosphate, 20% ethanol, and 30% H2O. Flow rate was set to 0.5 ml/min. 
Samples were injected into a Zorbax Eclipse XDB-C18 column, and the 
product was determined based on fluorescence detection of the OPA- 
conjugated amino acid, using excitation at 366 nm and emission at 
455 nm. Retention time for hypotaurine was 24.1 min, β-alanine 19.8 
min, and GABA 31.1 min. The software used for detecting the area was 
ChemStation 1100 from Agilent. Kinetic parameters were determined by 
nonlinear regression using the Michaelis–Menten equation in GraphPad 
Prism 8 (GraphPad Software, La Jolla, California, USA). 
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